Adrenoceptor subclassification: An approach to improved cardiovascular therapeutics

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 163-171

  Hieble, J Paul ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

(1L) Adrenoceptor; 4 Adrenoceptor; Benign prostatic hyperplasia; Cardiac arrhythmia; Congestive heart failure; Hypertension

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 [3 (4 METHOXYCARBONYL 4 PHENYL 1 PIPERIDINYL)PROPYL]AMIDE 5 METHYLAMIDE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 AMINO 2 [4 BENZYLOXYCARBONYL 3 [(TERT BUTYLAMINO)CARBONYL] 1 PIPERAZINYL] 6,7 DIMETHOXYQUINAZOLINE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; CARVEDILOL; CLONIDINE; CYCLAZOCINE; DOXAZOSIN; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; RECEPTOR SUBTYPE; RO 70 004; SL 89 0591; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; BLOOD VESSEL TONE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HYPERTENSION; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; SPECIES DIFFERENCE; STRESS INCONTINENCE;

ADRENERGIC AGENTS; ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; RECEPTORS, ADRENERGIC;

EID: 0034037332     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00030-8     Document Type: Conference Paper

References (83)

1. Ahlquist R.P. A study of the adrenotropic receptors. Am. J. Physiol. 153:1948;586-600.
2. 2-adrenoceptor antagonist. Eur. J. Pharmacol. 234:1993;137.
3. 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int. J. Obes. Relat. Metab. Disord. 20:1996;191-199.
4. Arch J.R.S., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thod V.E., Wilson C., Wilson S. Atypical β-adrenoceptors on brown adipocytes as target for anti-obesity drugs. Nature. 309:1984;163-165.
5. Beeley L.J., Berge J.M., Chapman H., Hieble P., Kelly J., Naselsky D.P., Rockell C.M., Young P.W. Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptors. Bioorg. Med. Chem. 3:1995;1693-1698.
6. Billman G.E. The effect of adrenergic receptor antagonists on cocaine-induced ventricular fibrillation: alpha but not beta adrenergic receptor antagonists prevent malignant arrhythmias independent of heart rate. J. Pharmacol. Exp. Ther. 269:1993;409-416.
7. 1-adrenoceptor antagonist tamsulosin. Am. J. Urol. 157:1997;190. Suppl.
8. Bril A., Slivjak M., DiMartino M., Feuerstein G.Z., Linee P., Poyser R.H., Ruffolo R.R. Jr., Smith E.F. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anesthetized minipigs: comparison with propranolol. Cardiovasc. Res. 26:1992;518-525.
9. Brune M.E., Katwala S.P., Milicic I., Buckner S.A., Ireland L.M., Kerwin J.F. Jr., Hancock A.A. Effects of selective and nonselective alpha-1 adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Pharmacology. 53:1996;356-368.
10. 2-adrenergic receptors. Pharmacol. Biochem. Behav. 22:1985;835-843.
11. 1b-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 94:1997;11589-11594.
12. Cawthorne, M.A., 1990. Thermogenic drugs. The potential of selective β-adrenoceptor agonists as anti-obesity drugs. In: Oomura, Y. et al. (Eds.), Progress in Obesity Research. John Libbey, pp. 567-574.
13. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Flohr K.H., Goldman S., Cobb F.R., Shah P.M., Saunders R., Fletcher R.D., Loeb H.S., Hughes V.C., Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N. Engl. J. Med. 314:1986;1547-1552.
14. Corr P.B., Heathers G.P., Yamada K.A. Mechanisms contributing to the arrhythmogenic influences of alpha1-adrenergic stimulation in the ischemic heart. Am. J. Med. 87(Suppl. 2A):1989;19S-25S.
15. 2C-Adrenoceptors mediate norepinephrine-induced contraction of rat caudal artery. FASEB J. 9:1995;A106.
16. Drew G.M. What do antagonists tell us about α-adrenoceptors? Clin. Sci. 68(Suppl. 10):1985;15s-19s.
17. 2-adrenergic receptor: expression and promoter characterization. Proc. Natl. Acad. Sci. U.S.A. 84:1987;6995-6999.
18. Eri L.M., Tveter K.J. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 154:1995;923-934.
19. 1 imidazoline receptor. J. Cardiovasc. Pharmacol. 20(Suppl. 4):1992;S1-S10.
20. Feuerstein G., Liu G.-L., Yue T.-L., Hheny H.-Y., Hieble J.P., Arch J.R.S., Ruffolo R.R. Jr., Ma X.-L. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur. J. Pharmacol. 351:1998;341-350.
21. Flavahan N.A., Vanhoutte P.M. α-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 7:1986;347-349.
22. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol. 49:1996;209-215.
23. 1-adrenoceptor subclassification. Br. J. Pharmacol. 121:1997;1127-1135.
24. 1C subtype. Mol. Pharmacol. 45:1994;703-708.
25. Garcia-Sainz J.A., Alcantara-Hernandez R., Vazquez-Prado J. α1-Adrenoceptor subtype activation increases proto-oncogene mRNA levels. Role of protein kinase C. Eur. J. Pharmacol. 342:1998;31-317.
26. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur. J. Med. Chem. 30:1995;299s-310s.
27. 1B-adrenoceptor antagonist. J. Med. Chem. 39:1996;4602-4607.
28. 1C specific compounds to treat benign prostatic hyperplasia. US Patent No 5,403847, April 4, 1995.
29. Hamburger S.A., Barone F.C., Feuerstein G.Z., Ruffolo R.R. Jr. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 43:1991;113-120.
30. Harrison S.N., Autelitano D.J., Wang B.H., Milano C., Du X.J., Woodcock E.A. Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha 1B adrenergic receptors. Circ. Res. 83:1998;1232-1240.
31. Hieble J.P., Kolpak D.C. In vivo effects of SK&F 86466 on lipolysis in the rat and hamster. Pharmacol. Commun. 1:1992;109-118.
32. Hieble, J.P., Ruffolo, R.R., Jr., 1991. Effects of α- and β-adrenoceptors on lipids and lipoproteins. In: Witiak, D.T., Newman, H.A.I., Feller, D.R. (Eds.), Antilipidemic Drugs: Medicinal Chemical and Biochemical Aspects. Elsevier, Amsterdam, pp. 301-344.
33. 2-adrenoceptor subtypes: therapeutic implications. Expert Opin. Invest. Drugs. 6:1997;367-387.
34. Hieble J.P., Caine M., Zalaznik E. In vitro characterization of the α-adrenoceptors in human prostate. Eur. J. Pharmacol. 107:1985;111-117.
35. 1-adrenoceptors: consensus update. Pharmacol. Rev. 47:1995;267-270.
36. Hunt R.D., Capper L., O'Connell P. Clonidine in child and adolescent psychiatry. J. Child and Adolescent Psychopharmacol. 1:1990;87-102.
37. Hunt R.D., Arnsten A.F.T., Asbell M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psy. 34:1995;50-54.
38. 1 adrenergic activity in cardiomyopathic Syrian hamster. Am. J. Physiol. 29:1991;H80-H88.
39. Kaumann A.J. Is there a third heart β-adrenoceptor? Trends Pharmacol. Sci. 10:1989;316-320.
40. Kaumann A.J., Molenaar P. Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;667-681.
41. Kaumann A.J., Preitner F., Sarsero D., Molenaar P., Revelli J.P., Giacobino J.P. (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative β4 adrenoceptors in both wild-type and β3 adrenoceptor knockout mice. Mol. Pharmacol. 53:1998;670-675.
42. 1L-Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br. J. Pharmacol. 123:1998;1359-1366.
43. 1-adrenoceptor antagonists on blood pressure and prostatic pressure in the anesthetized dog. J. Urol. 44:1994;52-57.
44. Kenny B., Ballard S., Blagg J., Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. 40:1997;1293-1315.
45. Kirby R.S., Pool J.L. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past present and future. Br. J. Urol. 80:1997;521-532.
46. 1A-adrenergic receptor subtype mediates biochemical, molecular and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:1993;15374-15380.
47. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 214:1967;597-598.
48. Langer S.Z. Presynaptic regulation of catecholamine release. Br. J. Pharmacol. 60:1974;481-497.
49. Langin D., Portillo M.P., Saulnier-Blanche J., Lafontan M. Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species. Eur. J. Pharmacol. 199(1974):1991;291-301.
50. 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br. J. Urol. 80:1997;606-611.
51. 1 adrenergic receptor subtypes. Cardiovasc. Res. 27:1993;839-844.
52. 1L-adrenoceptor in tissue selectivity: Part I. J. Pharmacol. Exp. Ther. 271:1997;1272-1283.
53. 2-adrenergic receptor subtypes b and c. Science. 273:1996;803-805.
54. 2a-adrenergic receptor subtype. Science. 273:1996;801-803.
55. McCafferty J.P., Naselsky D.P., Hieble J.P. Characterization of postjunctional α-adrenoceptors in the pithed mouse. Gen. Pharmacol. 33:1999;99-105.
56. Mizobe T., Maghsoudi K., Sitwala K., Tianzhi G., Ou J., Maze M. Antisense technology reveals the alpha 2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J. Clin. Invest. 98:1996;1076-1080.
57. 3H -prazosin binding Mol. Pharmacol. 29:1986;321-330.
58. Munoz M., Bancroft J., Beard M. Evaluating the effects of an alpha-2-adrenoceptor antagonist on erectile function in the human male. Psychopharmacology. 115:1994;471-477.
59. 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. 99:1990;197-201.
60. 1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem. 41:1998;5320-5333.
61. Packer M., Bristow M.R., Cohn N.J.et al. Carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334:1996;1349-1355.
62. 1b adrenergic receptor antagonist. J. Med. Chem. 41:1998;1205-1208.
63. Ramage A.G., Wyllie M.G. A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats. Eur. J. Pharmacol. 294:1995;645-650.
64. 2-antagonist, in the rat. J. Pharmacol. Exp. Ther. 236:1986;1-7.
65. Rohrer, D.K., Kobilka, B.K., 1998. Insights from in vivo modification of adrenergic receptor gene expression (review). In: Cho, A.K., Blaschke, T.F., Ho, I.K., Loh, H.H. (Eds.), Annual Review of Pharmacology and Toxicology, Vol. 38, pp. 351-373.
66. 1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. J. Biol. Chem. 271:1996;5839-5843.
67. 2-adrenoceptors as targets for circulating catecholamines in the maintenance of blood pressure in anaesthetized spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 7:1985;809-812.
68. Sennitt M.V., Arch J.R.S., Levy A.L., Simson D.L., Smith S.Q., Cawthorne M.A. Anti-hyperglycaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats. Biochem. Pharmacol. 34:1985;1279-1285.
69. Sennitt M.V., Kaumann A.J., Molenaar P., Beeley L.J., Young P.W., Kelly J., Chapman H., Henson S.M., Berge J.M., Dean D.K., Kotecha N.R., Morgan H.K., Rami H.K., Ward R.W., Thompson M., Wilson S., Smith S.A., Cawthorne M.A., Stock M.J., Arch J.R. The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities. J. Pharmacol. Exp. Ther. 285:1998;1084-1095.
70. Starke K., Montel H., Gayk W., Merker R. Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 285:1974;133-150.
71. Takeda, M., Komeyama, T., Tsutsui, T., Hatano, A., Obara, K., Mizusawa, T., Koizumi, T., 1996. Molecular expression and pharmacological functions of beta-3 adrenoceptor in human urinary bladder detrusor. In: Barbalias, G.A. (Ed.), International Continence Society: 26th Annual Meeting. Monduzzi Editore, Bologna, pp. 153-156.
72. 1-adrenoceptor activity in progression of cardiac hypertrophy in guinea pig hearts with pressure overload. Cardiovasc. Res. 23:1989;315-322.
73. Tang H.L., Zhu Q.M., Eglen R.M., Blue D.R. Jr. Effect of prazosin, Ro 70-0004 and RS-100329 in an anesthetized dog prostate/blood pressure model. Pharmacologist. 39:1997;45.
74. Taniguchi N., Hamada K., Ogasawara T., Ukai Y., Yoshikuni Y., Kimura K. NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur. J. Pharmacol. 318:1996;117-122.
75. Taniguchi N., Ukai Y., Tanaka T., Yano J., Kimura K., Moriyama N., Kawabe K. Identification of alpha 1-adrenoceptor subtypes in the human prostatic urethra. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;412-416.
76. 1L-adrenoceptor in tissue selectivity: Part II. J. Pharmacol. Exp. Ther. 281:1997;1272-1283.
77. Trendelenburg A.U., Sutej I., Wahl C.A., Molderings G.J., Rump L.C., Starke K. A re-investigation of questionable subclassifications of presynaptic alpha2-autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethra. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;721-737.
78. 1-adrenoceptor antagonist - first report: a single oral dose of conventional formulation in healthy male subjects. Rinsho Iyaku. 6:1990;2503-2528.
79. Wilde M.I., McTavish D. Tamsulosin. Drugs. 52:1996;883-898.
80. Willette R.N., Mitchell M.P., Ohlstein E.H., Lukas M.A., Ruffolo R.R. Jr. Evaluation of intrinsic sympathomimetric activity of bucindolol and carvedilol in rat heart. Pharmacology. 56:1998;30-36.
81. 1a adrenoceptor in Chinese hamster ovary cells. Br. J. Pharmacol. 119:1996;359P.
82. Wilson C., Wilson S., Piercy V., Sennitt M.V., Arch J.R.S. The rat lipolytic β-adrenoceptor: studies using novel β-adrenoceptor agonists. Eur. J. Pharmacol. 100:1984;309-319.
83. 1 adrenergic stimulation: a potential role for receptor mediated activation of sarcolemmal sodium-hydrogen exchange. Cardiovasc. Res. 29:1995;222-230.